DE69232122D1 - Rekombinante Viren, enthaltend eine künstliche proteolytische Schnittstelle. - Google Patents

Rekombinante Viren, enthaltend eine künstliche proteolytische Schnittstelle.

Info

Publication number
DE69232122D1
DE69232122D1 DE69232122T DE69232122T DE69232122D1 DE 69232122 D1 DE69232122 D1 DE 69232122D1 DE 69232122 T DE69232122 T DE 69232122T DE 69232122 T DE69232122 T DE 69232122T DE 69232122 D1 DE69232122 D1 DE 69232122D1
Authority
DE
Germany
Prior art keywords
recombinant viruses
replication
viral
interface
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69232122T
Other languages
English (en)
Other versions
DE69232122T2 (de
Inventor
Mark Feinberg
Raul Andino
Louise Weeks-Levy
Anne Reilly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Whitehead Institute for Biomedical Research
Original Assignee
Whitehead Institute for Biomedical Research
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute for Biomedical Research, American Cyanamid Co filed Critical Whitehead Institute for Biomedical Research
Application granted granted Critical
Publication of DE69232122D1 publication Critical patent/DE69232122D1/de
Publication of DE69232122T2 publication Critical patent/DE69232122T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69232122T 1991-12-06 1992-12-04 Rekombinante Viren, enthaltend eine künstliche proteolytische Schnittstelle. Expired - Fee Related DE69232122T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80489391A 1991-12-06 1991-12-06
US94779092A 1992-09-18 1992-09-18
PCT/US1992/010543 WO1993011251A1 (en) 1991-12-06 1992-12-04 Recombinant viruses comprising artificial proteolytic cleavage site

Publications (2)

Publication Number Publication Date
DE69232122D1 true DE69232122D1 (de) 2001-11-15
DE69232122T2 DE69232122T2 (de) 2002-05-16

Family

ID=27122734

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232122T Expired - Fee Related DE69232122T2 (de) 1991-12-06 1992-12-04 Rekombinante Viren, enthaltend eine künstliche proteolytische Schnittstelle.

Country Status (20)

Country Link
EP (1) EP0672157B1 (de)
JP (1) JPH07502403A (de)
KR (1) KR100272419B1 (de)
CN (1) CN1055726C (de)
AT (1) ATE206762T1 (de)
AU (1) AU674134B2 (de)
CA (1) CA2123804A1 (de)
CZ (1) CZ127394A3 (de)
DE (1) DE69232122T2 (de)
DK (1) DK0672157T3 (de)
ES (1) ES2163405T3 (de)
FI (1) FI942623A (de)
HU (1) HUT67346A (de)
IL (1) IL104003A0 (de)
MX (1) MX9206981A (de)
NO (1) NO942075L (de)
NZ (1) NZ246276A (de)
PT (1) PT672157E (de)
TW (1) TW403784B (de)
WO (1) WO1993011251A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU716466B2 (en) * 1995-09-27 2000-02-24 Medical Research Council Recombinant viruses incorporating a protease cleavable protein
FI20075063A0 (fi) 2007-02-01 2007-02-01 Vactech Oy Allergisen herkistymisen estäminen
WO2019179345A1 (en) 2018-03-19 2019-09-26 Boehringer Ingelheim (China) Investment Co., Ltd. Recombinant virus capable of stably expressing target proteins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1293591C (en) * 1985-01-11 1991-12-24 Charles A. Kettner Peptide substrates for detecting virus-specified protease activity
EP0321973B1 (de) * 1987-12-23 1993-11-03 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Expression der viral kodierten Protease P2A des HRV2
EP0406267A1 (de) * 1988-02-26 1991-01-09 Biosource Genetics Corporation Nichtnukleare chromosomale transformation
DD275259A1 (de) * 1988-08-30 1990-01-17 Akad Wissenschaften Ddr Verfahren zur konstruktion eines neuen expressionsvektors
WO1990011359A1 (en) * 1989-03-20 1990-10-04 Whitehead Institute For Biomedical Research Intracellular method of inhibiting hiv in mammalian cells
CA2055613A1 (en) * 1989-05-31 1990-12-01 Jeffrey W. Almond Poliovirus chimaeras
GB8912496D0 (en) * 1989-05-31 1989-07-19 Medical Res Council Vaccines
DE69033006T2 (de) * 1990-05-28 1999-09-23 Univ Osaka Res Found Herstellungsverfahren für ein plasmid mit fähigkeiten zu expression und prozessierung nach translation eines retroviralen gens, so erhaltenes plasmid und dessen expressionsprodukt
JPH05506999A (ja) * 1990-08-28 1993-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスプロティナーゼの活性をモニターするためのテスト系

Also Published As

Publication number Publication date
HU9401689D0 (en) 1994-09-28
ATE206762T1 (de) 2001-10-15
MX9206981A (es) 1994-08-31
IL104003A0 (en) 1993-05-13
CA2123804A1 (en) 1993-06-10
JPH07502403A (ja) 1995-03-16
DE69232122T2 (de) 2002-05-16
ES2163405T3 (es) 2002-02-01
KR100272419B1 (ko) 2001-02-01
WO1993011251A1 (en) 1993-06-10
NO942075D0 (no) 1994-06-03
DK0672157T3 (da) 2001-12-03
CZ127394A3 (en) 1995-11-15
EP0672157A1 (de) 1995-09-20
CN1075334A (zh) 1993-08-18
CN1055726C (zh) 2000-08-23
AU674134B2 (en) 1996-12-12
NZ246276A (en) 1996-08-27
NO942075L (no) 1994-08-03
EP0672157B1 (de) 2001-10-10
TW403784B (en) 2000-09-01
AU3242493A (en) 1993-06-28
FI942623A (fi) 1994-07-21
HUT67346A (en) 1995-03-28
KR950700421A (ko) 1995-01-16
FI942623A0 (fi) 1994-06-03
PT672157E (pt) 2002-04-29

Similar Documents

Publication Publication Date Title
DK0894126T3 (da) Alkalisk phosphatase-deficient trådformet svamp
ATE292685T1 (de) Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe
DE69109109T2 (de) Ubiquitinspezifische protease.
NO20053033D0 (no) Anvendelse av caspase enzymer for modning av konstruerte rekombinante polypeptidfusjoner.
DK1349944T3 (da) Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens
FI864624A (fi) Bombyx morin nuclear polyhedrosis -yhdistelmävirus ja menetelmiä proteiinien valmistamiseksi tätä käyttäen
ES2145742T3 (es) Uso de una proteasa de herpes.
FI921847A0 (fi) Farmaceutisk komposition som har endoproteolytisk aktivitet, foerfarande foer endoproteolytisk behandling av (prekursor)proteiner samt foerfarande foer (mikro)bio- logisk framstaellning av proteiner.
DE69232122T2 (de) Rekombinante Viren, enthaltend eine künstliche proteolytische Schnittstelle.
NO911557L (no) Fremgangsmaate for fremstilling av fremmedproteiner i streptomyceter.
FI946076A0 (fi) Modifioituja Kluyveromyces-hiivoja, valmistus ja käyttö
RU94030478A (ru) Рекомбинантный вирус, способ его получения, способ иммунизации, способ получения протеина, вакцинная композиция, применение рекомбинантного вируса
AR248047A1 (es) Procedimiento para la preparacion de una vacuna a base de virus del herpes bovina modificado tipo 1.
ATE386812T1 (de) Methode für die produktion von multivalenten influenza hämagglutinin vakzinen
DE3825118A1 (de) Expression der viral kodierten protease p2a des hrv2

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee